1
|
Marriott AE, Casewell NR, Lilley E, Gutiérrez JM, Ainsworth S. Improving in vivo assays in snake venom and antivenom research: A community discussion. F1000Res 2024; 13:192. [PMID: 38708289 PMCID: PMC11066530 DOI: 10.12688/f1000research.148223.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 03/06/2024] [Indexed: 05/07/2024] Open
Abstract
On the 26 th January 2023, a free to attend, 'improving in vivo snake venom research: a community discussion' meeting was held virtually. This webinar brought together researchers from around the world to discuss current neutralisation of venom lethality mouse assays that are used globally to assess the efficacy of therapies for snakebite envenoming. The assay's strengths and weaknesses were highlighted, and we discussed what improvements could be made to refine and reduce animal testing, whilst supporting preclinical antivenom and drug discovery for snakebite envenoming. This report summarises the issues highlighted, the discussions held, with additional commentary on key perspectives provided by the authors.
Collapse
Affiliation(s)
- Amy E Marriott
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, England, L3 5RF, UK
- Centre for Snakebite Research and Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
| | - Nicholas R Casewell
- Centre for Snakebite Research and Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
| | - Elliot Lilley
- National Centre for the Replacement, Reduction and Refinement of Animals in Research, London, NW1 2BE, UK
| | - José-María Gutiérrez
- Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, 11501-2060, Costa Rica
| | - Stuart Ainsworth
- Department of Infection Biology and Microbiomes, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, England, L3 5RF, UK
- Centre for Snakebite Research and Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, L3 5QA, UK
| |
Collapse
|
2
|
Sokol OO, Nikitin NA, Evtushenko EA, Karpova OV, Matveeva IN, Gryn SA, Popova VM, Ivanov IV, Fedorov YN, Litenkova IY. Protective Activity of Inactivated Rabies Vaccine Using Flagellin-Based Adjuvant. BIOCHEMISTRY. BIOKHIMIIA 2024; 89:574-582. [PMID: 38648774 DOI: 10.1134/s0006297924030155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2023] [Revised: 01/19/2024] [Accepted: 03/01/2024] [Indexed: 04/25/2024]
Abstract
Rabies is a zoonotic disease with high lethality. Most human deaths are associated with the bites received from dogs and cats. Vaccination is the most effective method of preventing rabies disease in both animals and humans. In this study, the ability of an adjuvant based on recombinant Salmonella typhimurium flagellin to increase protective activity of the inactivated rabies vaccine in mice was evaluated. A series of inactivated dry culture vaccine for dogs and cats "Rabikan" (strain Shchelkovo-51) with addition of an adjuvant at various dilutions were used. The control preparation was a similar series of inactivated dry culture vaccine without an adjuvant. Protective activity of the vaccine preparations was evaluated by the NIH potency test, which is the most widely used and internationally recommended method for testing effectiveness of the inactivated rabies vaccines. The value of specific activity of the tested rabies vaccine when co-administered with the adjuvant was significantly higher (48.69 IU/ml) than that of the vaccine without the adjuvant (3.75 IU/ml). Thus, recombinant flagellin could be considered as an effective adjuvant in the composition of future vaccine preparations against rabies virus.
Collapse
Affiliation(s)
- Olga O Sokol
- All-Russian Scientific Research and Technological Institute of Biological Industry, Biocombinat, Moscow Region, 141142, Russia
| | - Nikolai A Nikitin
- Faculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia.
| | | | - Olga V Karpova
- Faculty of Biology, Lomonosov Moscow State University, Moscow, 119234, Russia
| | - Irina N Matveeva
- All-Russian Scientific Research and Technological Institute of Biological Industry, Biocombinat, Moscow Region, 141142, Russia
- Shchelkovo Biocombinat Federal State Enterprise, Biocombinat, Moscow Region, 141142, Russia
| | - Svetlana A Gryn
- All-Russian Scientific Research and Technological Institute of Biological Industry, Biocombinat, Moscow Region, 141142, Russia
| | - Vera M Popova
- All-Russian Scientific Research and Technological Institute of Biological Industry, Biocombinat, Moscow Region, 141142, Russia
| | - Igor V Ivanov
- All-Russian Scientific Research and Technological Institute of Biological Industry, Biocombinat, Moscow Region, 141142, Russia
| | - Yuri N Fedorov
- All-Russian Scientific Research and Technological Institute of Biological Industry, Biocombinat, Moscow Region, 141142, Russia
| | - Irina Y Litenkova
- Shchelkovo Biocombinat Federal State Enterprise, Biocombinat, Moscow Region, 141142, Russia
| |
Collapse
|
3
|
Rüggeberg S, Wanglin A, Demirel Ö, Hack R, Niederhaus B, Bidlingmaier B, Blumrich M, Usener D. Progress towards the Replacement of the Rabbit Blood Sugar Test for the Quantitative Determination of the Biological Activity of Insulins (USP <121>) with an In Vitro Assay. Animals (Basel) 2023; 13:2953. [PMID: 37760353 PMCID: PMC10525547 DOI: 10.3390/ani13182953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 09/12/2023] [Accepted: 09/13/2023] [Indexed: 09/29/2023] Open
Abstract
For the quantification of insulin activity, United States Pharmacopeia (USP) general chapter <121> continues to require the rabbit blood sugar test. For new insulin or insulin analogue compounds, those quantitative data are expected for stability or comparability studies. At Sanofi, many rabbits were used to fulfil the authority's requirements to obtain quantitative insulin bioactivity data until the in vivo test was replaced. In order to demonstrate comparability between the in vivo and in vitro test systems, this study was designed to demonstrate equivalency. The measurement of insulin lispro and insulin glargine drug substance and drug product batches, including stress samples (diluted or after temperature stress of 30 min at 80 °C), revealed a clear correlation between the in vitro and in vivo test results. The recovery of quantitative in vitro in-cell Western (ICW) results compared to the in vivo test results was within the predefined acceptance limits of 80% to 125%. Thus, the in vitro ICW cell-based bioassay leads to results that are equivalent to the rabbit blood sugar test per USP <121>, and it is highly suitable for insulin activity quantification. For future development compounds, the in vitro in-cell Western cell-based assay can replace the rabbit blood sugar test required by USP <121>.
Collapse
Affiliation(s)
| | - Antje Wanglin
- CMC-Bioanalytics, R&D Sanofi, 65926 Frankfurt, Germany
| | - Özlem Demirel
- CMC-Bioanalytics, R&D Sanofi, 65926 Frankfurt, Germany
| | - Rüdiger Hack
- TIM Global Compliance and Policy, R&D Sanofi, 65926 Frankfurt, Germany
| | | | | | | | - Dirk Usener
- CMC-Bioanalytics, R&D Sanofi, 65926 Frankfurt, Germany
| |
Collapse
|
4
|
Barbalho GN, Falcão MA, Lopes JMS, Lopes JM, Contarato JLA, Gelfuso GM, Cunha-Filho M, Gratieri T. Dynamic Ex Vivo Porcine Eye Model to Measure Ophthalmic Drug Penetration under Simulated Lacrimal Flow. Pharmaceutics 2023; 15:2325. [PMID: 37765293 PMCID: PMC10534681 DOI: 10.3390/pharmaceutics15092325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2023] [Revised: 09/06/2023] [Accepted: 09/11/2023] [Indexed: 09/29/2023] Open
Abstract
Animal models are still used in the research and development of ophthalmic drug products, mainly due to the difficulty in simulating natural physiological conditions with in vitro models, as there is a lack of dynamic protection mechanisms. Therefore, developing alternative ophthalmic models that evaluate drug penetration in the cornea while applying dynamic protection barriers is a contemporary challenge. This study aimed to develop a dynamic ex vivo model using porcine eyes with a simulated lacrimal flow to evaluate the performance of pharmaceutical drug products. A glass donor cell to support a simulated tear flow was designed, optimized, and custom-made. The system was challenged with different formulations (with fluconazole) including excipients with different viscosities (poloxamer 407) and mucoadhesive properties (chitosan). The results were compared to those obtained from a conventional excised cornea model mounted in Franz-type diffusion cells. The dynamic model could differentiate formulations, while the static model did not, overestimating ex vivo drug penetrated amounts. Hence, the dynamic model with simulated tear flow showed to be a simple and promising new alternative method for the drug penetration of ophthalmic formulations that ultimately can reduce the number of animals used in research.
Collapse
Affiliation(s)
- Geisa N Barbalho
- Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia, Brasília 70910-900, DF, Brazil
| | - Manuel A Falcão
- Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia, Brasília 70910-900, DF, Brazil
| | | | - Júlia M Lopes
- Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia, Brasília 70910-900, DF, Brazil
| | - Jonad L A Contarato
- Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia, Brasília 70910-900, DF, Brazil
| | - Guilherme M Gelfuso
- Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia, Brasília 70910-900, DF, Brazil
| | - Marcilio Cunha-Filho
- Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia, Brasília 70910-900, DF, Brazil
| | - Tais Gratieri
- Laboratory of Food, Drugs, and Cosmetics (LTMAC), University of Brasilia, Brasília 70910-900, DF, Brazil
| |
Collapse
|
5
|
Poojary B, Viviani L, Sengupta A, Kalaivani M, Verma SR, Teng V, Makhija V, Prakash R, Bhatia N, Singh SN, Bruckner L, Halder M, Vree J. Future of TABST and LABST in the Indian Pharmacopoeia Monographs A Humane Society International/India Workshop Report. Biologicals 2023; 83:101665. [PMID: 37244127 DOI: 10.1016/j.biologicals.2023.101665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 11/30/2022] [Accepted: 02/07/2023] [Indexed: 05/29/2023] Open
Abstract
Humane Society International India (HSI India) organized and facilitated a workshop on the 'Future of Target Animal Batch Safety Test (TABST) and Laboratory Animal Batch Safety Test (LABST) in the Indian Pharmacopoeia (IP) Monographs'. The workshop hosted key Indian regulators from the Indian Pharmacopoeia Commission (IPC) and the Central Drugs Standard Control Organization (CDSCO), industry representatives from the Indian Federation of Animal Health Companies (INFAH), Asian Animal Health Association (AAHA), and international experts representing the European Directorate for the Quality of Medicines (EDQM), the International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (VICH), and multinational veterinary products manufacturers. The workshop was organized to encourage a bidirectional flow of information and to discuss the deletion of TABST and LABST from the veterinary vaccine monographs in the IP. This workshop was built from the symposium held by Humane Society International on the 'Global Harmonization of Vaccine Testing Requirements' held in 2019. This report details the outcomes of the workshop with proposed activities to be taken up as part of the next steps for the elimination or waiving of these tests.
Collapse
Affiliation(s)
| | - Laura Viviani
- Laura Viviani, Humane Society International, Switzerland
| | | | - M Kalaivani
- M Kalaivani, Indian Pharmacopoeia Commission, India
| | | | | | | | | | | | | | - Lukas Bruckner
- Lukas Bruckner, Consultant EDQM Nominated Expert, Switzerland
| | - Marlies Halder
- Marlies Halder, European Commission, Joint Research Centre, Italy
| | - Jeroen Vree
- Jeroen Vree, MSD Animal Heath, the Netherlands
| |
Collapse
|
6
|
Maxime V, Isabelle F, Antoine F, Hassall L, Lorenzo T, Wim VM, Romain P, Thierry L, Charline H, Paul S, Alexandre D. Development of a multiplex-based immunoassay for the characterization of diphtheria, tetanus and acellular pertussis antigens in human combined DTaP vaccines. J Immunol Methods 2023; 517:113483. [PMID: 37100343 DOI: 10.1016/j.jim.2023.113483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2022] [Revised: 03/08/2023] [Accepted: 04/21/2023] [Indexed: 04/28/2023]
Abstract
Routine batch quality testing before vaccine release, notably for potency evaluation, still relies on animal use for several animal and human vaccines. In this context, the VAC2VAC project is a public-private consortium of 22 partners funded by EU whose the main objective is to reduce the number of animal used for batch testing by developing immunoassays that could be implemented for routine potency assessment of vaccines. This paper focused on the development of a Luminex-based multiplex assay to monitor the consistency of antigen quantity and quality throughout the production process of DTaP vaccines from two human vaccine manufacturers. Indepth characterized monoclonal antibody pairs were used for development and optimization of the Luminex assay with non-adsorbed and adsorbed antigens and with complete vaccine formulations from both manufacturers. The multiplex assay demonstrated good specificity, reproducibility and absence of cross-reactivity. Analysis of over and underdosed formulations, heat and H2O2-degraded products as well as batch to batch consistency of vaccines from both manufacturers brought the proof of concept for a future application of the multiplex immunoassay as a useful tool in the frame of DTaP vaccine quality control.
Collapse
Affiliation(s)
| | - Feck Isabelle
- Sciensano, Quality of Vaccines and Blood Products, Belgium
| | | | - Laura Hassall
- National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, United Kingdom
| | | | - Van Molle Wim
- Sciensano, Quality of Vaccines and Blood Products, Belgium
| | | | | | - Hoebreck Charline
- Jefferson Wells consultant on assignment at GlaxoSmithKline, Belgium
| | - Stickings Paul
- National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, United Kingdom
| | | |
Collapse
|
7
|
Jia Q, Wang S, Yu M, Wang Q, Yan F. Two QSAR models for predicting the toxicity of chemicals towards Tetrahymena pyriformis based on topological-norm descriptors and spatial-norm descriptors. SAR AND QSAR IN ENVIRONMENTAL RESEARCH 2023; 34:147-161. [PMID: 36749040 DOI: 10.1080/1062936x.2023.2171478] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 01/17/2023] [Indexed: 06/18/2023]
Abstract
Quantitative structure-activity relationship (QSAR) is important for safe, rapid and effective risk assessment of chemicals. In this study, two QSAR models were established with 1230 chemicals to predict toxicity towards Tetrahymena pyriformis using multiple linear regression (MLR) method. The topological(T)-QSAR model was developed by using topological-norm descriptors generated from the topological structure, and the spatial(S)-QSAR model were built with spatial-norm descriptors obtained from the three-dimensional structure of molecules and topological-norm descriptors. The r2training and r2test are 0.8304 and 0.8338 for the T-QSAR model, and 0.8485 and 0.8585 for the S-QSAR model, which means that T-QSAR model and S-QSAR model can be used to predict toxicity quickly and accurately. In addition, we also conducted validation on the developed models. Satisfying validation results and statistical parameters demonstrated that QSAR models based on the topological-norm descriptors and spatial-norm descriptors proposed in this paper could be further utilized to estimate the toxicity of chemicals towards Tetrahymena pyriformis.
Collapse
Affiliation(s)
- Q Jia
- School of Marine and Environmental Science, Tianjin Marine Environmental Protection and Restoration Technology Engineering Center, Tianjin University of Science and Technology, Tianjin, PR China
| | - S Wang
- School of Marine and Environmental Science, Tianjin Marine Environmental Protection and Restoration Technology Engineering Center, Tianjin University of Science and Technology, Tianjin, PR China
| | - M Yu
- School of Chemical Engineering and Material Science, Tianjin University of Science and Technology, Tianjin, PR China
| | - Q Wang
- School of Chemical Engineering and Material Science, Tianjin University of Science and Technology, Tianjin, PR China
| | - F Yan
- School of Chemical Engineering and Material Science, Tianjin University of Science and Technology, Tianjin, PR China
| |
Collapse
|
8
|
Development of an In Vitro Test Method to Replace an Animal-Based Potency Test for Pertactin Antigen in Multivalent Vaccines. Vaccines (Basel) 2023; 11:vaccines11020275. [PMID: 36851153 PMCID: PMC9965796 DOI: 10.3390/vaccines11020275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 01/20/2023] [Accepted: 01/24/2023] [Indexed: 01/31/2023] Open
Abstract
There is increasing interest to replace animal-based potency assays used routinely to test vaccines, since they are highly variable, are costly, and present ethical concerns. The development of relevant in vitro assays is part of the solution. Using pertactin (PRN) antigen as an example in DTaP-IPV (diphtheria, tetanus, acellular pertussis, and inactivated poliovirus) vaccines, a PRN antigenicity ELISA was developed using two monoclonal antibodies with a high affinity to unique PRN epitopes, relevance to human immune responses, and evidence of functionality. The ELISA measured consistent PRN antigenicity between the vaccine lots and was validated to demonstrate its accuracy, precision, linearity, and specificity. Notably, the PRN antigenicity ELISA was more sensitive than the mouse-based potency test and could more effectively differentiate between degraded and intact vaccine lots compared to the in vivo test. From these studies, the PRN antigenicity ELISA is proposed as an in vitro replacement for the in vivo potency test for PRN in DTaP-IPV-based formulations. Important considerations in this study included comprehensive antibody characterization, testing of multiple vaccine lots, method validation, and comparison to animal-based potency. Together, these factors form part of an overall strategy that ensures reliable and relevant in vitro assays are developed to replace animal tests.
Collapse
|
9
|
Zhang X, Wu X, He Q, Wang J, Mao Q, Liang Z, Xu M. Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays. Expert Rev Vaccines 2023; 22:270-277. [PMID: 36779650 DOI: 10.1080/14760584.2023.2178421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
INTRODUCTION Potency is a critical quality attribute for controlling quality consistency and relevant biological properties of vaccines. Owing to the high demand for animals, lengthy operations and high variability of in vivo methods, in vitro alternatives for human vaccine potency assays are extensively developed. AREAS COVERED Herein, in vivo and in vitro methods for potency assays of previously licensed human vaccines were sorted, followed by a brief description of the background for substituting in vivo methods with in vitro alternatives. Based on the analysis of current research on the substitution of vaccine potency assays, barriers and suggestions for substituting were proposed. EXPERT OPINION Owing to the variability of in vivo methods, the correlation between in vivo and in vitro methods may be low. One or more in vitro method(s) that determine the vaccine antigen content and functions, should be established. Since the substitution involves with the change of critical quality attributes and specifications, the specifications of in vitro methods should be appropriately set to maintain the efficacy of vaccines. For novel vaccines in research and development, in vitro methods for monitoring the consistency and relevant biological properties, should be established based on reflecting the immunogenicity of vaccines.
Collapse
Affiliation(s)
- Xuanxuan Zhang
- Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Xing Wu
- Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Qian He
- Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Junzhi Wang
- Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Qunying Mao
- Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Zhenglun Liang
- Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| | - Miao Xu
- Institute of Biological Products, Division of Hepatitis and Enterovirus Vaccines, National Institutes for Food and Drug Control, Beijing, China
| |
Collapse
|
10
|
Dierick JF, Halder M, Jungbaeck C, Lorenz J, Préaud JM, Riou P, Tesolin L, Uhlrich S, Van Molle W, Vandeputte J. The consistency approach for the substitution of in vivo testing for the quality control of established vaccines: practical considerations and progressive vision. OPEN RESEARCH EUROPE 2022; 2:116. [PMID: 37645306 PMCID: PMC10446066 DOI: 10.12688/openreseurope.15077.2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 12/06/2022] [Indexed: 08/31/2023]
Abstract
The aim of this letter is to share the discussions and proposals made by the VAC2VAC consortium on how to support the deployment of the "Consistency Approach" for quality control of established vaccines and thus facilitate the substitution of in vivo testing. This work answers specific questions about " what does a control strategy according to the consistency testing look like" and " how to submit a control strategy defined according to the consistency testing". Some topics were answered in a very straightforward manner. This was the case when the deployment of the consistency approach and the corresponding changes in vaccines control strategy was supported by the generic application of procedures already described in regulatory guidelines/requirements and related to the establishment or change in the control strategy of vaccines. The application of other procedures required more specific attention and some were deeply debated before reaching a proposal. The key outcomes of this work are that robust science must be used to develop a substitution strategy and generate supportive data packages. And this good science can best occur with good scientific collaboration between the different parties involved. Therefore, early interaction between manufacturers and competent authorities before and during dossier submission is critical to success. The consistency approach, when approved and in place, will ensure vaccine products of assured quality reach the patient in a more efficient manner than when relying on in vivo testing. Adapting the mindset was one of the major hurdles to a progressive vision but there is now consensus between manufacturers and competent authorities to foster the elimination of in vivo testing for routine vaccine release testing.
Collapse
Affiliation(s)
| | - Marlies Halder
- Joint Research Centre, European Commission, Via E. Fermi 2749, Ispra (VA), 21027, Italy
| | | | - Julie Lorenz
- Zoetis Inc., 333 Portage St, Kalamazoo, MI, 49007, USA
| | | | - Patrice Riou
- Sanofi Vaccine, 1541 avenue marcel Mérieux, Marcy l’Etoile, 69280, France
| | - Lorenzo Tesolin
- Quality of Vaccines and Blood Products, Sciensano, 14 rue J. Wytsman, Brussels, 1050, Belgium
| | - Sylvie Uhlrich
- Sanofi Vaccine, 1541 avenue marcel Mérieux, Marcy l’Etoile, 69280, France
| | - Wim Van Molle
- Quality of Vaccines and Blood Products, Sciensano, 14 rue J. Wytsman, Brussels, 1050, Belgium
| | | |
Collapse
|
11
|
Miura K, Pham TP, Lee SM, Plieskatt J, Diouf A, Sagara I, Coelho CH, Duffy PE, Wu Y, Long CA. Development and Qualification of an Antigen Integrity Assay for a Plasmodium falciparum Malaria Transmission Blocking Vaccine Candidate, Pfs230. Vaccines (Basel) 2022; 10:vaccines10101628. [PMID: 36298492 PMCID: PMC9607959 DOI: 10.3390/vaccines10101628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 09/26/2022] [Accepted: 09/27/2022] [Indexed: 11/16/2022] Open
Abstract
During development of a subunit vaccine, monitoring integrity of the recombinant protein for process development and quality control is critical. Pfs230 is a leading malaria transmission blocking vaccine candidate and the first to reach a Phase 2 clinical trial. The Pfs230 protein is expressed on the surface of gametes, and plays an important role in male fertility. While the potency of Pfs230 protein can be determined by a standard membrane-feeding assay (SMFA) using antibodies from immunized subjects, the precision of a general in vivo potency study is known to be poor and is also time-consuming. Therefore, using a well-characterized Pfs230 recombinant protein and two human anti-Pfs230 monoclonal antibodies (mAbs), which have functional activity judged by SMFA, a sandwich ELISA-based in vitro potency assay, called the Antigen Integrity Assay (AIA), was developed. Multiple validation parameters of AIA were evaluated to qualify the assay following International Conference on Harmonization (ICH) Q2(R1) guidelines. The AIA is a high throughput assay and demonstrated excellent precision (3.2 and 5.4% coefficients of variance for intra- and inter-assay variability, respectively) and high sensitivity (>12% impurity in a sample can be detected). General methodologies and the approach to assay validation described herein are amenable to any subunit vaccine as long as more than two functional, non-competing mAbs are available. Thus, this study supports future subunit vaccine development.
Collapse
Affiliation(s)
- Kazutoyo Miura
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
- Correspondence:
| | - Thao P. Pham
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
| | - Shwu-Maan Lee
- PATH’s Malaria Vaccine Initiative (MVI), Washington, DC 20001, USA
| | - Jordan Plieskatt
- PATH’s Malaria Vaccine Initiative (MVI), Washington, DC 20001, USA
| | - Ababacar Diouf
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
| | - Issaka Sagara
- Malaria Research and Training Centre, University of Science, Techniques and Technologies, Bamako 1805, Mali
| | - Camila H. Coelho
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA
| | - Patrick E. Duffy
- Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA
| | - Yimin Wu
- PATH’s Malaria Vaccine Initiative (MVI), Washington, DC 20001, USA
| | - Carole A. Long
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA
| |
Collapse
|
12
|
Alternative Methods to Current In Vivo Procedures to Address the 3Rs Tenet in Rabies Proficiency Testing. Viruses 2022; 14:v14081698. [PMID: 36016320 PMCID: PMC9414609 DOI: 10.3390/v14081698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2022] [Revised: 07/26/2022] [Accepted: 07/29/2022] [Indexed: 11/23/2022] Open
Abstract
Canine rabies is responsible for an estimated 59,000 human deaths every year. In an attempt to reach the ZeroBy30 goal, robust disease surveillance coupled with improved diagnostics play a paramount role in ensuring reliable data and gradually attesting rabies control advancements. In this context, proficiency testing is organized to harmonize rabies diagnostic capacities. In most exercises, rabies-positive samples consist of brains collected from intracerebrally inoculated mice. This procedure causes distress and severe suffering to animals, raising important ethical concerns that can no longer be ignored. In the last decades, the 3Rs tenet (Replace, Reduce, Refine) has been successfully implemented in several scientific areas, and we strongly support its application in the framework of rabies proficiency testing. Here, we discuss cell-based technologies as innovative sustainable in vitro candidate systems to replace in vivo experiments for the production of proficiency testing samples. The application of these alternative methods can allow completely in vitro or ex vivo production of rabies proficiency testing panels, which would represent an important replacement or reduction/refinement for current in vivo procedures.
Collapse
|
13
|
McAdams D, Estrada M, Holland D, Singh J, Sawant N, Hickey JM, Kumar P, Plikaytis B, Joshi SB, Volkin DB, Sitrin R, Cryz S, White JA. Concordance of in vitro and in vivo measures of non-replicating rotavirus vaccine potency. Vaccine 2022; 40:5069-5078. [PMID: 35871866 PMCID: PMC9405915 DOI: 10.1016/j.vaccine.2022.07.017] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 06/16/2022] [Accepted: 07/14/2022] [Indexed: 12/03/2022]
Abstract
Rotavirus infections remain a leading cause of morbidity and mortality among infants residing in low- and middle-income countries. To address the large need for protection from this vaccine-preventable disease we are developing a trivalent subunit rotavirus vaccine which is currently being evaluated in a multinational Phase 3 clinical trial for prevention of serious rotavirus gastroenteritis. Currently, there are no universally accepted in vivo or in vitro models that allow for correlation of field efficacy to an immune response against serious rotavirus gastroenteritis. As a new generation of non-replicating rotavirus vaccines are developed the lack of an established model for evaluating vaccine efficacy becomes a critical issue related to how vaccine potency and stability can be assessed. Our previous publication described the development of an in vitro ELISA to quantify individual vaccine antigens adsorbed to an aluminum hydroxide adjuvant to address the gap in vaccine potency methods for this non-replicating rotavirus vaccine candidate. In the present study, we report on concordance between ELISA readouts and in vivo immunogenicity in a guinea pig model as it relates to vaccine dosing levels and sensitivity to thermal stress. We found correlation between in vitro ELISA values and neutralizing antibody responses engendered after animal immunization. Furthermore, this in vitro assay could be used to demonstrate the effect of thermal stress on vaccine potency, and such results could be correlated with physicochemical analysis of the recombinant protein antigens. This work demonstrates the suitability of the in vitro ELISA to measure vaccine potency and the correlation of these measurements to an immunologic outcome.
Collapse
Affiliation(s)
- David McAdams
- PATH, 2201 Westlake Ave, Seattle, WA 98122, United States
| | - Marcus Estrada
- PATH, 2201 Westlake Ave, Seattle, WA 98122, United States.
| | - David Holland
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, KS 66047, United States.
| | - Jasneet Singh
- PATH, 2201 Westlake Ave, Seattle, WA 98122, United States
| | - Nishant Sawant
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, KS 66047, United States
| | - John M Hickey
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, KS 66047, United States.
| | - Prashant Kumar
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, KS 66047, United States.
| | - Brian Plikaytis
- BioStat Consulting, LLC, 10429, Big Canoe, Jasper, GA 30143-5125, United States
| | - Sangeeta B Joshi
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, KS 66047, United States.
| | - David B Volkin
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, 2030 Becker Drive, Lawrence, KS 66047, United States.
| | - Robert Sitrin
- PATH, 2201 Westlake Ave, Seattle, WA 98122, United States.
| | - Stan Cryz
- PATH, 2201 Westlake Ave, Seattle, WA 98122, United States.
| | | |
Collapse
|
14
|
Viviani L, Reid K, Gastineau T, Milne C, Smith D, Levis R, Lei D, van Ooij M, Gilbert PA, Vandeputte J, Xie J, Madhuri L, Shaid S, Kubiak V, Suri R, Mizukami T, Shirasaki Y, Li X, Zhou YY, Trapkova A, Goel S, Prakash J, Subagio AA, Suwarni E, Jung KJ, Sanyal G, Das P, Coppens E, Wright D, Peng Z, Northeved H, Jungbäck C, Kirpitchenok T, Del Pace L, Seo B, Poojary B, Ottoni A. Accelerating Global Deletion of the Abnormal Toxicity Test for vaccines and biologicals. Planning common next steps. A workshop Report. Biologicals 2022; 78:17-26. [PMID: 35840492 PMCID: PMC9490484 DOI: 10.1016/j.biologicals.2022.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2022] [Accepted: 06/22/2022] [Indexed: 11/02/2022] Open
Abstract
This online workshop Accelerating Global Deletion of the Abnormal Toxicity Test for vaccines and biologicals. Planning common next steps was organized on October 14th, 2021, by the Animal Free Safety Assessment Collaboration (AFSA), the Humane Society International (HSI), the European Federation of Pharmaceutical Industries and Associations (EFPIA), in collaboration with the International Alliance of Biological Standardization (IABS). The workshop saw a participation of over a hundred representatives from international organizations, pharmaceutical industries and associations, and regulatory authorities of 28 countries. Participants reported on country- and region-specific regulatory requirements and, where present, on the perspectives on the waiving and elimination of the Abnormal Toxicity Test. With AFSA, HSI, EFPIA and IABS representatives as facilitators, the participants also discussed specific country/global actions to further secure the deletion of ATT from all regulatory requirements worldwide.
Collapse
Affiliation(s)
| | - Kirsty Reid
- European Federation of Pharmaceutical Industry and Association, Belgium
| | | | - Catherine Milne
- European Directorate for the Quality of Medicine and HealthCare (EDQM), France
| | | | | | | | | | | | | | | | | | | | - Vaughn Kubiak
- International Alliance for Biological Standardization, France
| | - Rajinder Suri
- Developing Countries Vaccine Manufacturers Network, India
| | | | | | | | | | - Alla Trapkova
- Federal State Budgetary Institution 'Scientific Centre for Expert Evaluation of Medicinal Products' of the Ministry of Health, Russian Federation
| | | | | | | | | | | | | | | | | | | | | | | | - Carmen Jungbäck
- International Alliance for Biologicals Standardization, France
| | | | | | - Borami Seo
- Humane Society International, South Korea
| | | | | |
Collapse
|
15
|
Schulte E, Arlt SP. What Kinds of Dogs Are Used in Clinical and Experimental Research? Animals (Basel) 2022; 12:ani12121487. [PMID: 35739824 PMCID: PMC9219481 DOI: 10.3390/ani12121487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2022] [Revised: 05/27/2022] [Accepted: 06/03/2022] [Indexed: 11/23/2022] Open
Abstract
Simple Summary The objective of this study was to evaluate the signalment of dogs used in veterinary research in six different specialties. In total, 150 randomly chosen clinical studies (25 studies per specialty) published between 2007 and 2019 were evaluated for the breed, sex, neuter status, age, and weight information of the dogs used. Breed information was given for 5.7% of the included animals. Beagles were used 1.9% of the time, which was a less significant role in research than we expected. Information about the sex of the dogs was lacking for 16.2% of the included animals, while age and weight information were missing for 22.7 and 32.7%, respectively. The neuter status was not given in 38.7% of the clinical studies. The results show deficits in the reporting of demographic data for the dogs. The need for an improvement in the documentation and/or reporting of animal signalment is obvious and should be addressed by authors, reviewers, and journal editors in the future. Abstract Background: Dogs are widely used in research to answer questions about canine or human conditions. For the latter, research dogs are often used as models, since they are physiologically more similar to humans than other species used in research and they share similar environmental conditions. From a veterinary perspective, research findings are widely based on academic research, and thus are generated under experimental conditions. In that regard, the question arises: do the dogs used for research adequately represent the dog population seen in veterinary practice? It may, for example, be assumed that Beagle dogs are often used as experimental animals. The objective of this study was to evaluate the signalment of dogs used in veterinary research. Furthermore, we aimed to assess other relevant criteria regarding the validity of clinical trials in the context of six different veterinary medicine specialties: cardiology, internal medicine, neurology, orthopaedics, reproduction, and surgery. Methods: A literature search was conducted and 25 studies per specialty were randomly selected. The breed, sex, neuter status, median age, and median weight of the dogs used for clinical studies (n = 150) published between 2007 and 2019 were evaluated. Results: In total, 596,542 dogs were used in the 150 trials. Breed information was given for 33,835 of these dogs (5.7%). Of the latter, 1.9% were Beagles. Nine clinical trials exclusively used Beagles. The most frequently used breeds were German Shepherds (7.3%), Labrador Retrievers (6.7%), and Golden Retrievers (4.7%). The major reporting deficits found were missing breed specification in 25.3% of the articles; missing information about the sex of the dogs in 16.2%; missing age and weight information in 22.7 and 32.7%, respectively; and missing neuter status in 38.7% of the clinical studies. The median sample size was 56 (Q1:29; Q3:365) dogs. Conclusions: The presented project revealed that Beagle dogs represent only a small proportion of dogs in veterinary research. Based on the evaluated publications, it seems that some relevant dog attributes differ between the specialties. The results, however, show deficits in the reporting of demographic data for the dogs. The need for an improvement in the documentation and/or reporting of animal signalment is obvious and should be addressed by authors, reviewers, and journal editors in the future.
Collapse
|
16
|
Perspective Technologies of Vaccination: Do We Still Need Old Vaccines? Vaccines (Basel) 2022; 10:vaccines10060891. [PMID: 35746498 PMCID: PMC9230923 DOI: 10.3390/vaccines10060891] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Accepted: 05/19/2022] [Indexed: 12/10/2022] Open
|
17
|
Jia Q, Wang J, Yan F, Wang Q. A QSTR model for toxicity prediction of pesticides towards Daphnia magna. CHEMOSPHERE 2022; 291:132980. [PMID: 34813852 DOI: 10.1016/j.chemosphere.2021.132980] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 11/15/2021] [Accepted: 11/17/2021] [Indexed: 06/13/2023]
Abstract
Because of the large amount of pesticides discharged into rivers, adverse effects could be induced to aquatic organisms. Daphnia magna is often used as an indicator organism to evaluate the toxicity of pesticides. In this study, a quantitative structure-toxicity relationship (QSTR) model was established based on norm descriptors for predicting the acute toxicity of pesticides to Daphnia magna. The model results showed the good predictability (Rtraining2 = 0.8045, Rtesting2 = 0.8224). The validation results of internal validation, external validation, Y-randomization test and application domain analysis demonstrated the model's stability, reliability and robustness. Therefore, the above results indicate that norm descriptors might be universal for describing the relationship between the toxicity and structures of pesticides compounds. Moreover, some pesticides' toxicities without experimental data were also predicted by this model.
Collapse
Affiliation(s)
- Qingzhu Jia
- School of Marine and Environmental Science, Tianjin Marine Environmental Protection and Restoration Technology Engineering Center, Tianjin University of Science and Technology, 13St. 29, TEDA, 300457, Tianjin, PR China
| | - Junli Wang
- School of Marine and Environmental Science, Tianjin Marine Environmental Protection and Restoration Technology Engineering Center, Tianjin University of Science and Technology, 13St. 29, TEDA, 300457, Tianjin, PR China
| | - Fangyou Yan
- School of Chemical Engineering and Material Science, Tianjin University of Science and Technology, 13St. 29, TEDA, 300457, Tianjin, PR China.
| | - Qiang Wang
- School of Chemical Engineering and Material Science, Tianjin University of Science and Technology, 13St. 29, TEDA, 300457, Tianjin, PR China
| |
Collapse
|
18
|
Volokhov DV, Fry AM, Furtak V, Jones RM, Musiychuk K, Norikane J, Green BJ, Srinivas GB, Streatfield SJ, Yusibov V. An ELISA-based antigenicity test of rabies recombinant glycoprotein cannot predict its protective potency in vivo. Mol Cell Probes 2022; 63:101815. [DOI: 10.1016/j.mcp.2022.101815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Accepted: 03/18/2022] [Indexed: 11/15/2022]
|
19
|
Johnson L, Aglas L, Soh WT, Geppert M, Hofer S, Hofstätter N, Briza P, Ferreira F, Weiss R, Brandstetter H, Duschl A, Himly M. Structural Alterations of Antigens at the Material Interface: An Early Decision Toolbox Facilitating Safe-by-Design Nanovaccine Development. Int J Mol Sci 2021; 22:10895. [PMID: 34639235 PMCID: PMC8509464 DOI: 10.3390/ijms221910895] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2021] [Revised: 09/30/2021] [Accepted: 10/04/2021] [Indexed: 12/18/2022] Open
Abstract
Nanomaterials have found extensive interest in the development of novel vaccines, as adjuvants and/or carriers in vaccination platforms. Conjugation of protein antigens at the particle surface by non-covalent adsorption is the most widely used approach in licensed particulate vaccines. Hence, it is essential to understand proteins' structural integrity at the material interface in order to develop safe-by-design nanovaccines. In this study, we utilized two model proteins, the wild-type allergen Bet v 1 and its hypoallergenic fold variant (BM4), to compare SiO2 nanoparticles with Alhydrogel® as particulate systems. A set of biophysical and functional assays including circular dichroism spectroscopy and proteolytic degradation was used to examine the antigens' structural integrity at the material interface. Conjugation of both biomolecules to the particulate systems decreased their proteolytic stability. However, we observed qualitative and quantitative differences in antigen processing concomitant with differences in their fold stability. These changes further led to an alteration in IgE epitope recognition. Here, we propose a toolbox of biophysical and functional in vitro assays for the suitability assessment of nanomaterials in the early stages of vaccine development. These tools will aid in safe-by-design innovations and allow fine-tuning the properties of nanoparticle candidates to shape a specific immune response.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | - Martin Himly
- Department of Biosciences, University of Salzburg, 5020 Salzburg, Austria; (L.J.); (L.A.); (W.T.S.); (M.G.); (S.H.); (N.H.); (P.B.); (F.F.); (R.W.); (H.B.); (A.D.)
| |
Collapse
|
20
|
van den Biggelaar RHGA, Hoefnagel MHN, Vandebriel RJ, Sloots A, Hendriksen CFM, van Eden W, Rutten VPMG, Jansen CA. Overcoming scientific barriers in the transition from in vivo to non-animal batch testing of human and veterinary vaccines. Expert Rev Vaccines 2021; 20:1221-1233. [PMID: 34550041 DOI: 10.1080/14760584.2021.1977628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
INTRODUCTION Before release, vaccine batches are assessed for quality to evaluate whether they meet the product specifications. Vaccine batch tests, in particular of inactivated and toxoid vaccines, still largely rely on in vivo methods. Improved vaccine production processes, ethical concerns, and suboptimal performance of some in vivo tests have led to the development of in vitro alternatives. AREAS COVERED This review describes the scientific constraints that need to be overcome for replacement of in vivo batch tests, as well as potential solutions. Topics include the critical quality attributes of vaccines that require testing, the use of cell-based assays to mimic aspects of in vivo vaccine-induced immune responses, how difficulties with testing adjuvanted vaccines in vitro can be overcome, the use of altered batches to validate new in vitro test methods, and how cooperation between different stakeholders is key to moving the transition forward. EXPERT OPINION For safety testing, many in vitro alternatives are already available or at an advanced level of development. For potency testing, in vitro alternatives largely comprise immunochemical methods that assess several, but not all critical vaccine properties. One-to-one replacement by in vitro alternatives is not always possible and a combination of methods may be required.
Collapse
Affiliation(s)
- Robin H G A van den Biggelaar
- Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | | | - Rob J Vandebriel
- Centre for Health Protection, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands
| | - Arjen Sloots
- Intravacc (Institute for Translational Vaccinology), Bilthoven, The Netherlands
| | | | - Willem van Eden
- Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
| | - Victor P M G Rutten
- Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.,Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Pretoria, South Africa
| | - Christine A Jansen
- Division of Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.,Cell Biology and Immunology Group, Department of Animal Sciences, Wageningen University and Research, Wageningen, The Netherlands
| |
Collapse
|
21
|
In Vitro Characterization of the Innate Immune Pathways Engaged by Live and Inactivated Tick-Borne Encephalitis Virus. Vaccines (Basel) 2021; 9:vaccines9060664. [PMID: 34204532 PMCID: PMC8234070 DOI: 10.3390/vaccines9060664] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2021] [Revised: 06/07/2021] [Accepted: 06/15/2021] [Indexed: 12/28/2022] Open
Abstract
Tick-borne encephalitis virus (TBEV) infection can lead to inflammation of the central nervous system. The disease can be effectively prevented by whole inactivated virus vaccines. Here, we investigated the innate immune profile induced in vitro by the antigen component of the vaccines, inactivated TBEV (I-TBEV), to gain insights into the mechanism of action of the TBE vaccine as compared to the live virus. To this end, we exposed human peripheral blood mononuclear cells (PBMCs) to inactivated and live TBEV and assessed cellular responses by RNA sequencing. Both inactivated and live TBEV significantly induced an interferon-dominated gene signature and an increased RIG-I-like receptor (RLR) expression. Using pathway-specific inhibitors, we assessed the involvement of pattern recognition receptors in the sensing of inactivated or live TBEV. Only RLR pathway inhibition significantly suppressed the downstream cascade induced by I-TBEV, while responses to the replicating virus were impacted by the inhibition of RIG-I-like, as well as Toll-like, receptors. Our results show that inactivated and live TBEV predominantly engaged an interferon response in our in vitro PBMC platform, and indicate RLRs as the main pattern recognition receptors involved in I-TBEV sensing.
Collapse
|
22
|
Ahmed U, Ahmed R, Masoud MS, Tariq M, Ashfaq UA, Augustine R, Hasan A. Stem cells based in vitro models: trends and prospects in biomaterials cytotoxicity studies. Biomed Mater 2021; 16:042003. [PMID: 33686970 DOI: 10.1088/1748-605x/abe6d8] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Advanced biomaterials are increasingly used for numerous medical applications from the delivery of cancer-targeted therapeutics to the treatment of cardiovascular diseases. The issues of foreign body reactions induced by biomaterials must be controlled for preventing treatment failure. Therefore, it is important to assess the biocompatibility and cytotoxicity of biomaterials on cell culture systems before proceeding to in vivo studies in animal models and subsequent clinical trials. Direct use of biomaterials on animals create technical challenges and ethical issues and therefore, the use of non-animal models such as stem cell cultures could be useful for determination of their safety. However, failure to recapitulate the complex in vivo microenvironment have largely restricted stem cell cultures for testing the cytotoxicity of biomaterials. Nevertheless, properties of stem cells such as their self-renewal and ability to differentiate into various cell lineages make them an ideal candidate for in vitro screening studies. Furthermore, the application of stem cells in biomaterials screening studies may overcome the challenges associated with the inability to develop a complex heterogeneous tissue using primary cells. Currently, embryonic stem cells, adult stem cells, and induced pluripotent stem cells are being used as in vitro preliminary biomaterials testing models with demonstrated advantages over mature primary cell or cell line based in vitro models. This review discusses the status and future directions of in vitro stem cell-based cultures and their derivatives such as spheroids and organoids for the screening of their safety before their application to animal models and human in translational research.
Collapse
Affiliation(s)
- Uzair Ahmed
- Department of Bioinformatics and Biotechnology, Government College University Faisalabad, Faisalabad 38000 Punjab, Pakistan
| | | | | | | | | | | | | |
Collapse
|